The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract from research to therapy英文文献.pdfVIP

Review The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy Expert Rev. Gastroenterol. Hepatol. 2(1), 125–133 (2008). Eyal Sagiv and CD24 was first described in the early 1980s and only attributed to scattered publications, Nadir Arber† referred to as a cell surface molecule in hematopoiesis. Recently, studies are accumulating to † show that CD24 conveys a function in cell-to-cell interaction and regulation of proliferation Author for correspondence and adhesion. CD24 appears to be highly expressed in a large variety of human cancers and to Integrated Cancer Prevention contribute to the acceleration of tumor growth and metastases shedding by binding to Center, Tel Aviv Medical Center, Tel Aviv, Israel platelet (P)-selectin, L1 and by evoking – to date unknown – intracellular signal pathways. Tel: +972 3697 4968 Anti-CD24 monoclonal antibodies thus act as a promising cancer treatment as was shown in Fax: +972 3695 0339 the setting of gastrointestinal cancers. Recent articles also correlate CD24 expression with the identification of ‘tumor stem cells’. narber@post.tau.ac.il KEYWORDS: cancer treatment • CD24 • GI cancer • monoclonal antibody • oncogene • P-selectin • signal transduction • tumor stem cell Co